Pérez Valle Isabel, Varela Trastoy Pilar, Mancebo Mata Alejo
Aparato Digestivo, Hospital Universitario de Cabueñes, España.
Aparato Digestivo, Hospital Universitario de Cabueñes.
Rev Esp Enferm Dig. 2021 Mar;113(3):186-188. doi: 10.17235/reed.2020.7230/2020.
It has been demonstrated that ustekinumab (UST) is effective as an induction and maintenance therapy in patients with Crohn's disease (CD). However, a significant number of patients experience an insufficient response or a secondary non-response. We report six cases from our center that underwent a rescue treatment by changing maintenance treatment to weight-adjusted intravenous UST, obtaining a subsequent clinical improvement.
已证明乌司奴单抗（UST）作为克罗恩病（CD）患者的诱导和维持治疗是有效的。然而，相当数量的患者反应不足或出现继发性无反应。我们报告了来自我们中心的6例患者，他们通过将维持治疗改为按体重调整的静脉注射UST进行了挽救治疗，随后临床症状得到改善。
